Lanean...
Benefits and harms of roflumilast in moderate to severe COPD
BACKGROUND: Roflumilast, a phosphodiesterase 4 inhibitor, was approved for the prevention of COPD exacerbations. It is unclear in which patients roflumilast will have a favorable benefit-harm balance. Our aim was to quantitatively assess the benefits and harms of roflumilast (500 mcg per day) compar...
Gorde:
| Argitaratua izan da: | Thorax |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2013
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4455881/ https://ncbi.nlm.nih.gov/pubmed/24347460 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2013-204155 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|